Risk factors for mortality in patients undergoing peritoneal dialysis: a systematic review and meta-analysis

Abstract

Aim

Inconsistent investigations of the risk factors for all-cause mortality in patients undergoing peritoneal dialysis (PD) were reported. The present meta-analysis aimed to assess the impact of some clinical characteristics on the risk of mortality in PD patients.

Methods

PubMed and Embase were systematically searched for studies evaluating the risk factors for all-cause mortality in PD patients. Hazard ratio (HR) and 95% confidence interval (CI) were derived using a random-effect or fixed-effect model considering the heterogeneity across studies.

Result

A total of 26 studies were included in this meta-analysis in accordance with the inclusion and exclusion criteria. Age, primary cardiovascular diseases, diabetes mellitus, and high level of alkaline phosphatase showed significant positive associations with elevated risk of all-cause and cardiovascular mortality in PD patients, while hemoglobin acted as a benefit factor. Furthermore, early onset of peritonitis, high peritoneal transport status, elevated body mass index and high-sensitivity C-reactive protein could also considerably increase the risk of all-cause mortality. The absolute serum level of magnesium, potassium, and uric acid required to improve survival in PD patients should be verified further.

Conclusions

Multiple factors could affect the risk of mortality in PD patients.

Keywords:

• Cardiovascular mortality
• meta-analysis
• mortality
• peritoneal dialysis
• risk factor

Introduction

Peritoneal dialysis (PD) is one of the major renal replacement therapies for patients with end-stage kidney disease (ESKD) [1]. The number of PD patients has been increasing in numerous developing countries. However, the long-term survival rate of PD patients remains low [2]. Additionally, cardiovascular disease (CVD) and death are highly prevalent in patients with ESKD [3,4]. These findings may be attributed to chronic inflammation, disturbed mineral metabolism, primary CVD, and other physical conditions. For instance, commonly accepted nutritional markers, such as serum albumin (ALB) level, serum creatinine (Cr) level, hemoglobin (Hb) level, and body mass index (BMI), might be used to assess prognosis of patients with chronic kidney disease (CKD) [5,6]. However, other studies reported a poor predictive value of serum ALB, serum Cr, and other characteristics of PD patients for all-cause mortality or cardiovascular outcomes [7,8]. Furthermore, the prognostic values of various physiological ions have not been well determined [9–12]. This meta-analysis aimed to identify the risk factors for mortality in PD patients to improve prognosis.

Materials and methods

Search strategy

This meta-analysis was conducted following the meta-analysis of observational studies in epidemiology (MOOSE) guidelines [13]. PubMed and Embase were searched for studies conducted from January 2000 to December 2020. Studies evaluating the risk factors for all-cause mortality or cardiovascular mortality in patients undergoing PD satisfied the inclusion criteria in the present meta-analysis. We used ((((‘peritoneal dialysis’ OR ‘renal dialysis’ OR ‘renal replacement therapy’ OR ‘chronic kidney disease’ OR ‘end-stage kidney disease’ OR ‘ESKD’) AND (‘mortality’ OR ‘death’ OR ‘survival’) AND (‘potassium’ OR ‘magnesium’ OR ‘peritonitis’ OR ‘body mass index’ OR ‘albumin’ OR ‘hemoglobin’) AND Clinical Trial[ptyp]) as the search terms. Moreover, the references of all the relevant original articles were manually reviewed to identify additional eligible studies.

Selection criteria

Respective study was assessed by two independent reviewers, and any disagreements between the two reviewers were resolved by another independent reviewer. The inclusion criteria were as follows: (1) studies including patients undergoing PD; (2) studies mentioning at least one of the risk factors, namely, age, Hb level, serum ALB level, BMI, diabetes mellitus (DM), serum potassium level, serum magnesium level, peritonitis, peritoneal transport characteristics, alkaline phosphatase (ALP) level, high-sensitivity C-reactive protein (hs-CRP) level, and uric acid (UA) level; (3) studies evaluating all-cause mortality; (4) studies reporting statistical data including hazard ratio (HR) and 95% confidence interval (CI). Studies without adjustment for specific potential confounders and non-English studies were excluded. Finally, a total of 26 studies were included.

Statistical analysis

All statistical analyses were conducted in Review Manager 5.3 software. HR adjusted for confounding variables and 95% CI were extracted from included studies. Each HR was transformed into a log HR, and the standard error was calculated based on the corresponding 95% CI. Statistical heterogeneity among studies was evaluated using the I² index [14]. A random-effect model was adopted if the I² index was >50%, demonstrating substantial heterogeneity; otherwise, a fixed-effect model was employed. A p value <0.05 was considered statistically significant. Furthermore, Egger’s tests were performed to assess potential publication bias, and a sensitivity analysis was conducted to determine the robustness of the conclusion by excluding each article from the meta-analysis.

Results

Literature search

A total of 4421 potentially relevant articles were retrieved from PubMed and Embase. After screening titles and abstracts, 112 duplicate studies and 4139 non-relevant studies were excluded. The remaining 170 studies were subjected to full-text assessment, and 144 trials were further removed based on the following criteria: (i) unavailable full-text, (ii) non-inclusion of PD patients, or (iii) unavailable desired outcomes. Finally, 26 papers were included in our systematic review [9–12,15–36]. This meta-analysis had a good inter-reviewer agreement (κ = 0.851). A flowchart summarizing the selection process is presented in Figure 1.

Figure 1. Flow diagram of the trail selection process.

Figure 2. Forest plots for the hazard risk (HR) between risk factors and all-cause mortality in PD patients (a) age (per 1 year increase); (b) cardiovascular disease; (c) diabetes mellitus; (d) hypersensitive-C reaction protein (mg/l); (e) hemoglobin (g/dl); (f) albumin (mg/dl); (g) high body mass index; (h) low body mass index; (i) alkaline phosphatases (U/l); (j) magnesium (high vs low); (k) uric acid (high vs low); (l) potassium (low vs high); (m) early on-set of peritonitis; (n) peritoneal transport status (high vs low)).

Figure 3. Forest plots for the hazard risk (HR) between risk factors and cardiovascular mortality in PD patients (a) age (per 1 year increase); (b) diabetes mellitus; (c) cardiovascular disease; (d) albumin (mg/dl); (e) hemoglobin (g/dl); (f) uric acid (high vs low); (g) potassium (low vs high); (h) alkaline phosphatases (U/l)).

Study characteristics

The baseline characteristics of included studies are shown in Table 1. Each study included 102-10,692 patients, and median follow-up duration ranged from 13.0 months to 52.8 months. Among these studies, 26 trials ascertained all-cause mortality, and 15 studies enrolled the outcomes of cardiovascular mortality. All studies reported HR adjusted for possible confounders, such as age, sex, BMI, DM, and laboratory indices.

Table 1. Baseline of characteristics of studies of systematic review and meta-analysis.

Study	Country	Type	Sample size	Mean age (year)	Percentage Male (%)	Percentage DM (%)	Follow-up duration (month)	Reported outcome	Adjusted factors
Ye H 2017 [15]	China	Retrospec-tive	1321	48.1 ± 15.3	58.7	23.5	34 (21–48）	All-cause and cardiovas-cular mortality	age, sex, DM, CVD, ALB, 24 h urine output, Hb, P
Xiang S 2019 [16]	China	Retrospec-tive	9405	52.5 ± 14.6	54.9	12.2	34.5 ± 23.2	All-cause and cardiovas-cular mortality	DM, CVD, Ca, RRF, Hb, Cr, ALB, PTH, potassium, natrium, P, fasting plasma glucose
Xue Y 2019 [17]	China	Retrospec-tive	748		50.1		6.23 (2.423– 11.652)	All-cause and cardiovas-cular mortality	age, Cr, urea, ALB, Hb, Ca, DM, P, DBP, CHD, eGFR
Hwang SD 2019 [18]	Korea	Retrospec-tive	6071	65.8 ± 13.7	57.5	36.1	90.96 ± 54.34	All-cause mortality	age, sex, DM, ALB, Hb, SBP, DBP, PNA, cholesterol, total body water, urine duration, Kt/Vurea week total, Cr clearance weekly
Lai KJ 2018 [19]	China	Retrospec-tive	492	53.5 ± 15.3	48	34.6	36.4	All-cause and cardiovas-cular mortality	age, sex, BMI, smoking, medication, comorbidi-ties, PD related parameters, laboratory data
Jung HY 2018 [20]	Korea	Prospective	953	57.2 ± 12.8	58.6	45	36.0 ± 16.2	All-cause and cardiovas-cular mortality	age, sex, BMI, SBP, DBP, DM, smoking, myocardial infarction, LDL, HDL, total cholesterol, dialysis vintage
Liu Y 2017 [21]	China	Retrospec-tive	667		42.9	24.7	32.64	All-cause and cardiovas-cular mortality	age, sex, 24 h urinary output, Hb, ALB, Ca, AST, P, ALT, PTH
Rhee CM 2014 [22]	USA	Retrospec-tive	9244	54 ± 15	52	49	32.4 (15.6–51.6)	All-cause mortality	age, sex, race, DM, BMI, CVD, smoking, ferritin, dialysis vintage, primary insurance, marital status
Liu X 2014 [23]	China	Retrospec-tive	1021	47.5 ± 15.5	59.1	22.8	31 (19–45)	All-cause and cardiovas-cular mortality	age, sex, 24 h urinary output, BP, ALB, Hb, comorbidity score, ALT, AST, P, Ca, iPTH, phosphate binders use
Li W 2017 [24]	China	Retrospec-tive	1228	46.96 ± 14.9	61.2	25.5	35 (18.7–52.3)	All-cause and cardiovas-cular mortality	age, sex, BMI, DM, CVD, Hb, ALB, TG, uric acid, MAP, rGFR
Lee S 2017 [25]	Korea	Prospective	1152	54 (45–64)	56.5	34.8	52.8 ± 20.4	All-cause mortality	age, sex, MCCI, BMI, ALB, ALP, Ca, P, SGA, uric acid
Kim YK 2014 [26]	Korea	Prospective	900	56 ± 12	57	32	24 (14 − 27)	All-cause mortality	age, sex, DM, Davies comorbidity score
Prasad N 2014 [27]	India	Prospective	328	52.6 ± 12.6	73.8	53.7	20.0 ± 14.3	All-cause mortality	age, SGA, DM, ALB, comorbidities, rGFR
Tian Y 2016 [28]	China	Retrospec-tive	294	50.8 ± 14.0	62.2	14.3	33.3 (17.3–52.8)	All-cause mortality	age, time to first peritonitis, cholesterol, DM, eGFR, ALB, CCI score
Feng S 2016 [29]	China	Retrospec-tive	189	57.5 ± 15.9	56.1	51.3		All-cause mortality	age, DM, ALB, CRP, RRF
Liu X 2016 [30]	China	Retrospec-tive	1778	47.4 ± 15.6	59.5	25.3	35 (17–56)	All-cause and cardiovas-cular mortality	age, sex, PD inception
Yang X 2016 [9]	China	Retrospec-tive	10692	56 ± 16	55	40	13 (7–23)	All-cause mortality	age, sex, DM, race, primary insurance, geographic location, ESRD reason, prior transplant, comorbidities, laboratory
Cai K 2016 [10]	China	Retrospec-tive	253	58 ± 16	55.3	22.9	29 (4–120)	All-cause and cardiovas-cular mortality	age, sex, DM, rGFR, MAP, urinary output, sodium, Cr clearance, malnutrition, bone disorder-related factors
Wu X 2016 [31]	China	Retrospec-tive	1068	48.0 ± 15.4	58.8	23.1	21.7 ± 14.1	All-cause mortality	age, heart disease, DM, stroke, MAP, Hb, ALB, hs-CRP, time to first peritonitis
Xiong L 2015 [32]	China	Retrospec-tive	1263	47.8 ± 15.0	58.6	24.1	25.3 (3.03– 82.07)	All-cause and cardiovas-cular mortality	age, sex, DM, CVD, MAP, Hb, ALB, hs-CRP, TG, rGFR, Kt/Vurea, total cholesterol
Xu Q 2014 [12]	China	Retrospec-tive	886	48.5 ± 15.4	57.1	23.9	31 (0.5–81.0)	All-cause and cardiovas-cular mortality	age, sex, BMI, DM, Hb, ALB, CCI, hs-CRP
Dong J 2014 [33]	China	Retrospec-tive	2264	58.1 ± 15.5	49.1	37.7	26.5 (13.6–43.6)	All-cause and cardiovas-cular mortality	age, sex, RRF, ALB, Hb, P, CRP, CVD, DM, MAP, BMI, LDL
Torlen K 2012 [34]	Sweden	Retrospec-tive	10468	56 ± 16	53	49	27	All-cause and cardiovas-cular mortality	age, sex, DM, race, dialysis vintage, Hb, primary insurance, marital status, BMI, smoking, CVD, cancer, ferritin, ALP, WBC, ALB, Cr, Ca, P, PTH, total iron binding capacity
Angela 2003 [35]	China	Prospective	246	55 ± 12	52	31	24 (2–34)	All-cause and cardiovas-cular mortality	age, weight, height, BMI, CVD, DBP, LV mass index, LV end-diastolic diameter, LV ejection fraction, LV fractional shortening
Guan JC 2015 [36]	China	Retrospec-tive	102		57.8		22.6	All-cause mortality	age, ALB, Hb, glycated Hb A1c, clearance of Cr, RRF, PNA
Rumpsfe-ld M 2006 [37]	Australia	Retrospec-tive	3702	59.4 ± 14.8	53.9	38.1		All-cause mortality	age, sex, race, smoking, BMI, weekly Kt/V, RRF, vintage year, PD modality, hyperten-sion,chronic lung disease, DM, coronary artery disease, peripheral vascular disease, cerebrovas-cular disease

Hb: hemoglobulin; PTH: parathyroid hormone; DM: diabetes mellitus; RRF: residual renal function; ALB: albumin; hs-CRP: hypersensitive C-reactive protein; CVD: cardiovascular disease; TG: total triglyceride; WBC: white blood cell; LDL: low density lipoprotein; HDL: high density lipoprotein; BMI: body mass index; BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; Ca: calcium; Cr: creatinine; eGFR: estimated glomerular filtration rate; rGFR: residual glomerular filtration rate; MAP: mean arterial pressure; SGA: subjective global assessment; PNA: protein equivalent of total nitrogen appearance; MCCI, modified Charlson comorbidity index.

Risk factors for all-cause mortality in patients undergoing PD

As shown in Table 2 and Figure 2, age (HR: 1.04, 95% CI: 1.04–1.05, p < 0.00001), DM (HR: 1.58, 95% CI: 1.41–1.78, p < 0.00001), primary CVD (HR: 1.72, 95% CI: 1.17–2.52, p = 0.006), high BMI (HR: 1.15, 95% CI: 1.04–1.28, p = 0.005), ALP level (HR: 2.11, 95% CI: 1.86–2.39, p < 0.00001), early onset of peritonitis (HR: 1.83, 95% CI: 1.26–2.64, p = 0.001), high hs-CRP level (HR: 1.37, 95% CI: 1.04–1.82, p = 0.03), and high peritoneal transport status (HR: 1.39, 95% CI: 1.10–1.76, p = 0.006) showed significant positive associations with all-cause mortality in PD patients. A fixed-effect model was applied to analyze variables because the I² index was <50%. Sensitivity analysis was conducted in CVD and hs-CRP, given the substantial heterogeneity, while the conclusion was not affected. Egger’s test revealed no significant publication bias for any abovementioned risk factors (p for age = 0.712, p for DM = 0.458, p for CVD = 0.801, p for high BMI = 0.738, p for hs-CRP = 0.113, and p for ALP = 0.221).

Table 2. Factors influencing the risk of all-cause mortality in PD patients.

Risk factors	HR (95% CI)	p Value	p Value for heterogeneity (p, I^2)
Age (per 1 year increase)	1.04 (1.04–1.05)	p < 0.00001***	p = 0.30 I^2=17%
CVD	1.72 (1.17–2.52)	p = 0.006**	p < 0.0001 I^2=87%
DM	1.58 (1.41–1.78)	p < 0.00001***	p = 0.09 I^2=46%
Hs-CRP (mg/l)	1.37 (1.04–1.82)	p = 0.03	p < 0.00001 I^2=94%
Hb (g/dl)	0.87 (0.83–0.90)	p < 0.00001***	p = 0.41 I^2=0%
ALB (mg/dl)	0.71 (0.42–1.21)	p = 0.21	p < 0.00001 I^2=93%
High BMI (kg/m^2)	1.17 (1.04–1.31)	p = 0.007	p = 0.40 I^2=0%
Low BMI (kg/m^2)	1.20 (0.83–1.73)	p = 0.34	p = 0.009 I^2=71%
ALP (U/l)	2.11 (1.86–2.39)	p < 0.00001***	p = 0.95 I^2=0%
Magnesium (high vs low)	0.19 (0.02–2.22)	p = 0.18	p = 0.03 I^2=73%
Uric acid (high vs low)	0.93 (0.48–1.79)	p = 0.83	p < 0.0001 I^2=91%
Potassium (low vs high)	1.25 (0.97–1.60)	p = 0.08	p = 0.10 I^2=56%
Early on-set of peritonitis	1.83 (1.26–2.64)	p = 0.001***	p = 0.41 I^2=0%
Peritoneal transport status (high vs low)	1.39 (1.10–1.76)	p = 0.006	p = 0.21 I^2=36%

HR: hazard ratio; CI: confidence interval; ALB: albumin; DM: diabetes mellitus; CVD: cardiovascular diseases; hs-CRP: hypersensitive C-reactive protein; Hb: hemoglobulin; ALP: alkaline phosphatases; GFR: glomerular filtration rate; BMI: body mass index.

**p < 0.01.

***p < 0.001.

Furthermore, the pooled HR suggested a significant association between Hb level (HR: 0.87, 95% CI: 0.83-0.90, p < 0.00001) and a low risk of all-cause mortality in PD patients. Egger’s test revealed no significant publication bias for Hb (p = 0.876).

Meanwhile, this study identified no associations between serum ALB, low BMI, high UA level, high magnesium level, low potassium level, and the risk of all-cause mortality in PD patients.

Risk factors for cardiovascular mortality in patients undergoing PD

As shown in Figure 3, the pooled HR indicated that age (HR: 1.04, 95% CI: 1.03–1.050, p < 0.00001), primary CVD (HR: 2.12, 95% CI: 1.39–3.23, p = 0.0005), DM (HR: 1.60, 95% CI: 1.30–1.96, p < 0.00001), and high ALP (HR: 2.39, 95% CI: 1.22–4.66, p = 0.01) might elevate the risk of cardiovascular mortality in PD patients. Moreover, Hb level (HR: 0.87, 95% CI: 0.81–0.94, p = 0.0002) acted as a protective factor for cardiovascular mortality. Egger’s test revealed no significant publication bias (p for age = 0.95, p for DM = 0.574, and P for CVD = 0.292). Serum ALB level, high UA level, and low potassium level did not significantly affect the risk of cardiovascular mortality (Table 3).

Table 3. Factors influencing the risk of cardiovascular mortality in PD patients.

Risk factors	HR (95% CI)	p Value	p Value for heterogeneity (p, I^2)
Age (per 1 year increase)	1.04 (1.03-1.05)	p < 0.00001***	p = 0.67 I^2=0%
DM	1.60 (1.30-1.96)	p < 0.00001***	p = 0. 60 I^2=0%
CVD	2.12 (1.39-3.23)	p = 0.0005***	p = 0. 01 I^2=77%
ALB (g/dl)	0.79 (0.61-1.02)	p = 0.07	p = 0.93 I^2=0%
Hb (g/dl)	0.87 (0.81-0.94)	p = 0.0002***	p = 0.83 I^2=0%
Uric acid (high vs low)	0.74 (0.23-2.45)	p = 0.63	p = 0.009 I^2=85%
Potassium (low vs high)	1.46 (0.67-3.16)	p = 0.34	p = 0.03 I^2=79%
ALP (U/l)	2.39 (1.22-4.66)	p = 0.01**	p = 0.96 I^2=0%

HR: hazard ratio; CI: confidence interval; ALB: albumin; Hb: hemoglobulin; DM: diabetes mellitus; CVD: cardiovascular diseases; ALP: alkaline phosphatases.

**p < 0.01.

***p < 0.001.

Discussion

The present meta-analysis of 26 studies, including a total of 66,735 patients, was considered as the first meta-analysis exploring the risk factors for all-cause and cardiovascular mortality in patients undergoing PD. It covered five prospective studies. Our results indicated that age, primary CVD, DM, and ALP level negatively affected the risk of all-cause and cardiovascular mortality. Furthermore, early onset of peritonitis, obesity, high hs-CRP level, and membrane transport status might elevate the risk of all-cause mortality. Hb level was found to have a beneficial impact on the risk of all-cause mortality, while serum ALB level had a slight beneficial impact.

In this meta-analysis, only articles with sufficient data to calculate HR and adjusted ones were included. In the existing study, functional status of patients undergoing PD might predict the risk of mortality, such as employment status and family education [37,38]. The use of medicine, such as angiotensin receptor blockers and oral active vitamin D, could also reduce the risk of major cardiovascular events and total mortality [39]. Notably, the associations between several clinical and laboratory characteristics of PD patients and all-cause mortality were still under debate.

In the present meta-analysis, age, primary CVD, DM, and high level of ALP were found to be the risk factors for both all-cause and cardiovascular mortality in patients undergoing PD. Additionally, patients with high BMI, high peritoneal transport status, high level of hs-CRP, and early onset of peritonitis also had an elevated risk of all-cause mortality. Primary DM and CVD might impair vascular endothelial cells and cause chronic inflammation, primarily leading to arterial stif-fness; it might predict the risk of fatal cardiovascular events and all-cause mortality. Furthermore, poor glycemic control was found to be an independent risk factor for mortality in PD patients [40,41]. A correlation between an increased BMI and improved outcomes in hemodialysis patients has been reported, although such a relationship is so far unknown in PD patients [42]. In this meta-analysis, we found that patients in the highest BMI group experienced poorer survival outcomes compared to those in the normal BMI group. Although a U-shaped relationship between underweight and mortality was observed previously [43], the association was not significant in our analysis. Obesity was shown to be related to a decline of residual renal function (RRF), adversely affecting survival [44]. However, the prognostic value of BMI might depend on race, total cholesterol level, inflammation status, and comorbidities. Mineral metabolism disorders are highly prevalence among patients with CKD, such as abnormal serum calcium, phosphorus, and parathyroid hormone concentrations. Hyperphosphatemia was shown to be correlated with elevated apoptosis and poor immune response, which might increase risk for mortality [45]. Serum ALP level is generally considered to indicate renal bone disease in patients with CKD. Additionally, high level of ALP might be associated with vascular calcification and osteomalacia. In this meta-analysis, high peritoneal membrane transport, assessed by the peritoneal equilibration test, was also found to be a risk factor for mortality. An increased rate of peritoneal membrane solute transport might enhance protein losses through peritoneal membrane leading to a malnutrition status. Guan et al. [35] reported that higher peritoneal transport status was not an independent predictor after adjusting for ALB level, Hb level, and RRF. Large-scale randomized clinical trials are required to verify this relationship. In addition, we showed that early onset of peritonitis and elevated hs-CRP level increased the risk of all-cause mortality significantly although there was significant heterogeneity among studies in terms of hs-CRP level. Two prospective and one retrospective study were included for hs-CRP as a continuous variable, with different sample sizes, country, and primary status of patients, which might account for the heterogeneous. Meanwhile, elevated Hb level was found to be a protective factor for all-cause mortality. Lower Hb level was commonly regarded as malnutrition, demonstrating the absence of intravenous iron or erythropoiesis-stimulating agent therapy.

Hypokalemia is common in PD patients, primarily affecting the cardiovascular system. Furthermore, patients with hypokalemia may have more comorbidities. We included three studies exploring the relationship between serum potassium level and mortality, which was presented as a categorical variable. Xu et al. [12] and Lee et al. [25] reported a serum potassium level of <3 mEq/L or <4.5 mmol/L to be an independent risk factor for all-cause mortality in PD patients. However, the baseline values in another study did not show this relationship [11]. The change or fluctuation in serum potassium level during PD might be more reliable to predict death risk in PD patients and should be investigated further. Magnesium, the fourth most abundant cation in the body, plays a key role in various biological processes. Tubular injuries might cause renal magnesium wasting. Serum magnesium level of <1.8 mg/dL was reported to be a risk factor after adjusting for baseline demographic characteristics and comorbidities, but the risk was attenuated after further adjustment for laboratory indices [9]. Furthermore, the beneficial effect of a serum magnesium level of >0.7 mmol/L might be different between male and female individuals [10]. Considering that lower serum magnesium is associated with a poor nutrition status and increased inflammation, the independent relationship between serum magnesium and mortality in PD patients should be evaluated,and an appropriate treatment to maintain the right serum magnesium level needs to be determined. UA is the final product of nucleotide metabolism, and it is primarily excreted from the kidney by glomerular filtration. High level of serum UA could be an endothelial toxin and aggravated endothelial function by activating the inflammatory pathway [46]; it is also associated with RRF loss [47]. However, we did not observe any significant association between hyperuricemia and mortality. Xiang et al. [16] studied the impact of high serum UA level on mortality in PD patients by divided them into five groups according to their serum UA level. Patients with UA > 7.28 mg/dL had a higher all-cause mortality compared to those in the middle group. Furthermore, UA < 6.06 mg/dL was found to be a risk factor only in an unadjusted model. The other two studies divided patients into three groups according to their UA level. However, Lai et al. [19] reported high serum UA level to be a protective factor for mortality. Serum UA level reflects patients’ nutrition condition, and a low serum UA level might lead to inflammation. Considering a potential U-shaped association between UA and mortality, a proper range of serum UA and treatments to lower serum UA level should be determined to improve survival. However, these outcomes might not be feasible because there are only few studies reporting such indices. To confirm this association, more studies were required.

Importantly, the present meta-analysis is the first one to explore the risk factors for all-cause mortality in PD patients. This study had a large enough sample size and HR adjusted for possible confounders. There was a debate about different risk factors in previous studies, and this meta-analysis might be more reliable to predict all-cause and cardiovascular mortality in PD patients.

This study has several limitations. First, individual studies adjusted for the different potential confounders, which might result in a high heterogeneity. Second, the present meta-analysis might have missed some unpublished articles without conference abstracts in line with the selection criteria. Third, although we observed a significant heterogeneity in the impact of CVD on mortality across studies, we did not perform a subgroup analysis according to race. Moreover, we applied a random-effect model in this meta-analysis. Fourth, this meta-analysis was not registered in PROSPERO, which might lead to a bias. However, importantly, this meta-analysis was conducted in accordance with the standards of systematic review. Furthermore, more data regarding the respective risk factors are recommended.

In conclusion, the present meta-analysis revealed that a considerable number of risk factors displayed significant associations with an elevated risk of all-cause and cardiovascular mortality in PD patients. A proper threshold for serum magnesium, potassium, and UA should be determined to improve the survival in PD patients. Since data on several indices were limited, more studies are required to confirm the findings of this meta-analysis.

Author contributions

Han Li and Shixiang Wang conceived and designed the experiment; Jialing Zhang searched the literature and acquired the data primarily, while Xiangxue Lu secondarily; Han Li settled any inconsistencies between these two authors; Han Li and Jialing Zhang analyzed and interpreted the data; Han Li, Jialing Zhang and Xiangxue Lu wrote the paper; Han Li obtained the funding. All authors read and approved the final manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data of this study are available from the corresponding author.

Additional information

Funding

This work was supported by National Natural Science Foundation of China [81670673] and Beijing Natural Science Foundation [7182060].